IPONZ
Marina Biotech this week announced that the Intellectual Property Office of New Zealand said it will grant the company a patent covering its unlocked nucleobase analog technology.
Marina Forms New Early-Stage Collaboration, Issued Notice of Allowance on Peptide Delivery Tech
Premium
The deal with an undisclosed "major pharmaceutical company" is focused on the evaluation of Marina's proprietary amphoteric liposomal formulations for pulmonary delivery.
According to MDRNA, the application claims siRNAs and delivery systems with therapeutic potential.